Review of existing literature in this area indicates that researchers should focus their attention on studying the role of KRAS mutations in early stage of pancreatic cancer to improve the early screening rate and, thereby, prolong the patient survival rate and improve the life quality in pancreatic cancer. This evidence concerns the gene KRAS and pancreatic neoplasm.